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Background: The pan-histone deacetylase inhibitor panobinostat is a potential therapy for 
malignant glioma, but it is water insoluble and does not cross the blood–brain barrier when 
administered systemically. In this article, we describe the in vitro and in vivo efficacy of a 
novel water-soluble nano-micellar formulation of panobinostat designed for administration by 
convection enhanced delivery (CED).
Materials and methods: The in vitro efficacy of panobinostat-loaded nano-micelles against 
rat F98, human U87-MG and M059K glioma cells and against patient-derived glioma stem cells 
was measured using a cell viability assay. Nano-micelle distribution in rat brain was analyzed 
following acute CED using rhodamine-labeled nano-micelles, and toxicity was assayed using 
immunofluorescent microscopy and synaptophysin enzyme-linked immunosorbent assay. 
We compared the survival of the bioluminescent syngenic F98/Fischer344 rat glioblastoma 
model treated by acute CED of panobinostat-loaded nano-micelles with that of untreated and 
vehicle-only-treated controls.
Results: Nano-micellar panobinostat is cytotoxic to rat and human glioma cells in vitro in a 
dose-dependent manner following short-time exposure to drug. Fluorescent rhodamine-labelled 
nano-micelles distribute with a volume of infusion/volume of distribution (Vi/Vd) ratio of four 
and five respectively after administration by CED. Administration was not associated with any 
toxicity when compared to controls. CED of panobinostat-loaded nano-micelles was associated 
with significantly improved survival when compared to controls (n=8 per group; log-rank test, 
P,0.001). One hundred percent of treated animals survived the 60-day experimental period 
and had tumour response on post-mortem histological examination.
Conclusion: CED of nano-micellar panobinostat represents a potential novel therapeutic option 
for malignant glioma and warrants translation into the clinic.
Keywords: glioma, micelle, convection enhanced delivery, panobinostat, HDAC inhibitor
Introduction
High-grade glioma (HGG) is the most common malignant primary brain tumor 
in adults, and its treatment represents an unmet clinical need in both children and 
adults. The age-specific incidence of HGG is bimodal, peaking in childhood and to a 
greater extent between 50 and 60 years of age. Despite current treatment involving a 
combination of surgery, systemic chemotherapy and radiotherapy, the prognosis of 
glioblastoma (GBM) is poor with a median survival of 14.6 months in adults.1 Many 
promising therapeutic agents for central nervous system (CNS) disorders have failed 
to attain clinical success due to the blood–brain barrier (BBB), which prevents the 
passage of agents from the systemic circulation into the brain. Systemic administration 
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of high drug doses may increase delivery to the brain, but 
this approach risks significant side effects and toxicity. Direct 
delivery of drugs to the brain facilitates bypass of the BBB. 
However, the therapeutic efficacy of drugs injected into the 
brain parenchyma and/or tumors is limited by minimal dif-
fusion from the site of injection and, consequently, small 
volumes of distribution. In 1994, the concept of convection 
enhanced delivery (CED) was introduced as a solution to the 
obstacles that limit therapeutic drug delivery to the CNS.2,3
CED describes continuous infusion of agents under pres-
sure through stereotactically placed micro-catheters.4 This 
method has several potential advantages over conventional 
drug delivery methods. CED facilitates highly accurate ana-
tomical drug targeting, delivery of high drug concentrations 
throughout clinically relevant volumes of brain tissue or tumor, 
and reduces systemic side effects. CED has been extensively 
investigated in the context of a wide range of CNS disorders in 
both preclinical and clinical trials, most notably for the treat-
ment of brain tumors and Parkinson’s disease.5–11 Drugs can 
be administered directly to the brain by CED in concentrations 
that would result in significant toxicity if given systemically. 
In contrast to delivery techniques that are dependent on diffu-
sion, CED enables the controlled, homogeneous distribution 
of drugs through large brain volumes.3 Furthermore, as CED 
leads to the displacement of extracellular fluid with infusate, it 
offers an opportunity to manipulate the extracellular environ-
ment of intrinsic malignant brain tumors.12–15
Panobinostat is a pan-histone deacetylase inhibitor 
(HDACi), which has recently gained the approval of the 
US Food and Drug Administration (FDA) and National 
Institute for Health and Care Excellence UK for the treat-
ment of relapsed myeloma in adults. Histone deacetylation 
results in chromatin remodeling and controls a number of 
cellular processes, including the regulation of transcription, 
transcription factor stability and cell survival. Inhibition 
of this histone deacetylation results in cell cycle arrest and 
apoptosis of tumor cells.16 Epigenetic events, such as histone 
acetylation, are believed to be critical processes that drive 
gliomagenesis in both adult and pediatric supratentorial HGG 
and in pediatric brainstem glioma, including diffuse intrinsic 
pontine glioma (DIPG).17,18 A recent drug screen of geneti-
cally diverse and clinically relevant ex vivo DIPG cell lines 
revealed panobinostat as the most efficacious drug currently 
in clinical use.19 Panobinostat therefore may be a particularly 
suitable drug candidate for both supratentorial and brainstem 
HGG chemotherapy in both adults and children.
Oral panobinostat has been studied in phase 1 and 2 
clinical trials in adult patients with progressive GBM. 
The phase 1 results describe a maximum tolerated dose 
of 30 mg three times per week, every other week when 
given in combination with bevacizumab, an anti-vascular 
endothelial growth factor monoclonal antibody.20 The 
phase 2 trial was stopped prematurely as it did not show a 
significant survival benefit when compared to control.21 In a 
recent clinical study of patients treated with panobinostat as a 
method of reactivating latent HIV to a therapeutic advantage, 
panobinostat was not detectable in the cerebrospinal fluid 
(CSF) at multiple time points post treatment, suggesting 
that treatment failure in patients with HGG may be due to 
poor BBB penetrance.22 A similar result has been reported 
in phase 1 data from children receiving oral panobinostat 
for the treatment of acute lymphoblastic leukemia and from 
nonhuman primate pharmacokinetic data.23,24 Direct intra-
tumoral infusion of panobinostat by CED is therefore of 
significant clinical interest for the treatment of supratentorial 
and brainstem HGG.
Panobinostat is very poorly water soluble (,1 mg/mL). 
The physicochemical characteristics and hydrophobicity of 
panobinostat make it an unlikely candidate for CED in its 
unmodified form.25 Chemical modification of panobinostat 
to achieve water solubility risks negation of its biochemical 
efficacy. To overcome these limitations, we investigated 
the delivery of panobinostat as a payload in nano-micellar 
form. A number of carrier vehicles exist that are capable of 
sequestering a strongly hydrophobic compound within the 
core of a particle measuring several tens of nanometers in 
diameter, which are dispersible in water.26 It is possible for 
these particulates to disseminate through the body and be 
taken up by cells, whereupon the drug payload is delivered 
by cellular mechanisms to the target site, facilitating bypass 
of the major efflux transporters of the BBB.27
Poloxamer 407 (P407) is an FDA-approved triblock 
copolymer consisting of hydrophobic polypropylene 
glycol units terminated at each end by hydrophilic poly-
ethylene glycol chains. The hydrophobic and hydrophilic 
interactions within the P407 molecule drive self-assembly 
into micelles ∼20 nm in diameter in aqueous solutions.28 It is 
possible for strongly hydrophobic drugs to be partitioned 
within the micelle core, such that they can be dispersed 
under physiological conditions as a colloid. Compounds 
that cannot be directly solubilized into the hydrophobic 
core through mixing alone can be formulated into particles 
by an emulsion-mediated solvent evaporation method.29,30 
This mechanism achieves drug concentrations that are far 
greater than normal for a species dissolved into aqueous 
physiological solutions. This has been previously dem-
onstrated by loading polymeric nano-micelles with the 
organometallic drug KP46.30
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We describe a series of experiments that demonstrate 
the in vitro efficacy of water-soluble panobinostat-loaded 
P407 nano-micelles (LBH589/P407) against commercially 
available and patient-derived HGG cell lines, their distri-
bution and toxicity after CED in normal rat brain, and the 
effect on survival when administered to the orthotopic F98 
rat glioma model by CED.
Materials and methods
Micelle synthesis and evaluation
Formulation of drug-loaded polymeric nano-micelles 
in artificial cerebrospinal fluid (aCSF)
A stock solution of 5% P407 in aCSF (Torbay Pharmaceuticals, 
Torbay, UK) was prepared by the direct dissolution of P407 
polymer into aCSF under magnetic stirring. Control solutions 
of unloaded polymeric nano-micelles were prepared by the 
addition of 0.5 mL of CHCl
3
 to 10 mL of a 5% P407 in aCSF 
solution (P407/aCSF) under stirring to form an emulsion. 
After a minimum of 15 minutes of stirring, the emulsion 
solution was transferred to a beaker and microwaved in ten 
seconds bursts with manual stirring until the CHCl
3
 was 
observed to evaporate. The aqueous nano-micelle product 
was then extracted from the beaker in a graduated syringe 
and passed through a 250-µm filter into a vial and then sealed. 
The critical micelle concentration for P407 at 25°C in water 
is 0.04%.31 This is much lower than the 5% used in making 
the stock solution in aCSF. We found that lower concentra-
tions of P407 during the drug-loading step failed to support 
the drug in solution.
Drug-loaded polymeric nano-micelle solutions were 
formed using the same process but with a given amount of 
panobinostat dissolved in the organic phase prior to addi-
tion to the aqueous phase. Stock of 0.5 mL (10 mg/mL) 
panobinostat (molecular weight [MW] =349.4; SelleckChem, 
Munich, Germany) in chloroform (CHCl
3
) was added to 
10 mL of stock P407/aCSF and emulsified before microwave 
treatment and filtration to produce a colloid with the equiva-
lent concentration of 0.5 mg/mL panobinostat. Nano-micelle 
solutions were prepared at lower loadings of drug by dilution 
of the 10 mg/mL stock chloroform solution before addition to 
the aqueous phase. Panobinostat-loaded P407 nano-micelles 
in aCSF solutions (LBH589/P407) were prepared in a drug 
concentration range of 0.083–0.5 mg/mL.
characterization of P407 nano-micelles
The size and charge of unloaded control and drug-loaded 
P407 nano-micelles were analyzed by dynamic light 
scattering (DLS) and zeta potential measurement using a 
Zetasizer Nano ZS (Malvern Instruments).
1H nuclear magnetic resonance (NMR) experiments 
to investigate the behavior of the drug-loaded polymeric 
nano-micelles over time and upon dilution were conducted 
on a Varian 600 MHz VNMRS NMR Spectrometer fit-
ted with a 5-mm HCN cold probe and using a double 
pulse field-gradient spin-echo water suppression pulse 
sequence.
1H diffusion-ordered NMR spectroscopy (DOSY NMR) 
was performed on a Varian 500 MHz VNMRS NMR 
Spectrometer fitted with a 5-mm AutoX DB-PFG probe 
to confirm the presence and diffusion coefficient of free 
panobinostat. Full sample preparation for NMR experiments 
is available in the Supplementary materials.
synthesis of rhodamine-labeled P407 nano-micelles
An amino-terminated P407 intermediate (P407-NH
2
) was 
synthesized and subsequently functionalized further with 
rhodamine through imidazole cross-linking using a method 
adapted from those previously described.32,33 For micelle-
labeling experiments, 0.05% of rhodamine-labeled P407 
to unlabeled P407/aCSF was determined to be optimal for 
fluorescent-imaging purposes.
In vitro experiments
cell culture
F98, U87-MG and M059K glioma cell lines (American 
Type Culture Collection, ATCC, Manassas, VA, USA) 
were grown following the supplier’s protocol and under 
standard conditions. In brief, U87-MG and F98 were cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum and 1% 
l-glutamine, whereas M059K cells were grown in DMEM/
Ham-F12, with 10% fetal bovine serum, 1.5% HEPES, 
1% l-glutamine and 1% nonessential amino acids at 37°C 
in a humidified atmosphere with 5% CO
2
. Reagents were 
purchased from Life Technologies (Paisley, UK) unless 
stated otherwise. Patient-derived glioma stem cell lines, 
G144 and G26 were obtained as a kind gift from Dr Colin 
Watts (University of Cambridge, Cambridge, UK) and 
Dr Steven Pollard (University of Edinburgh, Edinburgh, 
UK) and cultured following instructions from the host 
laboratories.34,35
Primary hippocampal cell culture
Neuronal cultures were obtained from the hippocampus of 
18-day-old Wistar rat embryos as previously described.36 
Cells were counted and plated on poly-d-lysine-coated 
10 mm coverslips (Sigma-Aldrich, Dorset, UK) at a density 
of 75,000 cells per coverslip.
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In vitro cell viability assay
Cellular cytotoxicity of LBH589/P407 nano-micelles was 
measured using a two-color fluorescent-based live/dead cell 
viability assay (Life Technologies). Cells were cultured in 
96-well plates and dosed with LBH589/P407 for 30 minutes, 
6 hours and 72 hours. After 72 hours, cells were washed with 
phosphate-buffered saline (PBS) and incubated with 2 µM 
calcein acetoxymethyl and 4 µM ethidium homodimer-1 for 
30 minutes at room temperature. Fluorescence was measured 
on a microplate reader (FLUOstar Omega; BMG Labtech), 
following the manufacturer’s protocol. All assays were per-
formed in triplicate using cells of three different passages. 
Experimental values were normalized against negative and 
positive controls.
generation of F98-luciferase-expressing cells
To create a bioluminescent glioma cell line, F98 rat glioma 
cells were transduced with firefly luciferase at a multiplicity 
of infection of 10 for 18 hours as described by the manu-
facturer (Cignal Lenti [Luc]; Qiagen, Manchester, UK), fol-
lowed by puromycin selection.
In vivo experiments
ceD procedure
Juvenile Wistar rats (225–275 g; Charles River, Margate, 
UK) were housed in the animal service unit facility at the 
University of Bristol. All animal-handling procedures and 
experiments were performed in accordance with the UK 
Animal Scientific Procedures Act 1986 and covered by UK 
Home Office licenses approved by the University of Bristol 
ethics committee and institutional review board (project 
licence: 30/2909).
Animals were anesthetized with intraperitoneal ketamine 
(Ketaset, 60 mg/kg; Pfizer Animal Health, Sandwich, UK) 
and medetomidine (Dormitor, 0.4 mg/kg; Pfizer Animal 
Health), and then placed in a stereotactic frame (David Kopf 
Instruments, Tujunga, CA, USA). A midline skin incision 
was made from glabella to occiput to expose bregma. CED 
procedures were performed using a custom-made catheter 
with an outer diameter of 0.22 mm and inner diameter of 
0.15 mm, composed of fused silica with a laser cut tip. The 
cannula was attached to a 1 mL syringe (Hamilton, Bonaduz, 
Switzerland) connected to a rate-controlled micro-infusion 
pump (World Precision Instruments Inc., Sarasota, FL, USA) 
and the tip placed at stereotactic coordinates derived from 
the Paxinos and Watson stereotactic rat brain atlas (0.75 mm 
rostral and 3 mm lateral to bregma, at a depth of 5 mm to 
target the striatum, and 2.5 mm to target the corpus callosum). 
Burr holes were drilled using a 2-mm drill.
All CED procedures were performed at an infusion rate 
of 2.5 µL/minute. On completion of infusion, the cannula 
was left in situ for 10 minutes to minimize reflux, and then 
it was withdrawn at a rate of 1 mm/minute. The wound was 
closed, and a dose of intramuscular buprenorphine (Centaur 
Services, Castle Cary, UK) was administered (30 µg/kg). 
The anesthetic was reversed with 0.1 mg/kg intraperito-
neal atipamezole hydrochloride (Pfizer Animal Health) 
in recovery procedures. At predetermined time points, 
animals were euthanized by anesthetic overdose with an 
intraperitoneal injection of 1 mL pentobarbital (Euthatal; 
Merial Animal Health, Harlow, UK). Then, either perfu-
sion fixed with 100 mL of PBS followed by 100 mL of 4% 
paraformaldehyde (PFA; Fisher Scientific, Loughborough, 
UK) in PBS (pH 7.4) or the brain was removed from the 
skull and placed on dry ice immediately for further analysis. 
If perfusion fixed, the brain was then removed from the 
skull, placed in 4% PFA for 48 hours and cryoprotected in 
30% sucrose (Melford Laboratories, Ipswich, UK) in PBS 
prior to sectioning.
Distribution analysis of rhodamine-labeled  
P407 nano-micelles
Fluorescent rhodamine-labeled P407 nano-micelles were 
infused into the striatum and white matter of Wistar rats 
for distribution analysis. Two groups of three animals were 
sacrificed at 0 and 48 hours post infusion.
Rat brains were then cut into 35 µm thick coronal sec-
tions using a Leica CM1850 cryostat (Leica Microsystems, 
Wetzlar, Germany) at -20°C and mounted on gelatin-subbed 
slides. Images were captured using the Stereo Investigator 
platform (MicroBrightField Bioscience, Williston, VT, USA) 
using a Leica DM5500 microscope (Leica Microsystems) 
and digital camera (MicroBrightField Bioscience). Images 
were analyzed with in-house software, which calculates the 
three-dimensional (3D) volume from automated segmen-
tation of fluorescent signal from serial two-dimensional 
(2D) images.
In vivo toxicity analysis
Toxicity was determined using quantitative analysis of 
the presynaptic protein synaptophysin and postmortem 
immunofluorescent microscopy after acute striatal infusion 
of unloaded P407 nano-micelles (P407/aCSF) in the left 
striatum and aCSF in the right striatum to serve as a control. 
Juvenile Wistar rats were assigned to experimental groups 
and sacrificed at 48 hours or 21 days in two groups of three 
animals for histological examination or synaptophysin 
enzyme-linked immunosorbent assay (ELISA).
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synaptophysin elIsa
Rats were euthanized by anesthetic overdose as described 
earlier, and their brains were removed and snap-frozen in 
liquid nitrogen. Synaptophysin ELISA was performed on rat 
brain homogenates at 48 hours and 21 days following CED of 
P407 aCSF or aCSF alone. An untreated age-matched control 
brain was used as an additional control. The ELISA protocol 
for measuring synaptophysin concentration was adapted 
for rat brain homogenates as previously described.37,38 All 
samples were tested in triplicate.
Immunofluorescent microscopy
Thirty five micrometer thick sections of PFA-fixed rat brain 
were mounted on gelatin-subbed slides. The sections were 
incubated with either mouse anti-rat NeuN, clone A60, 
biotin-conjugated (1:100; Millipore, Temecula, CA, USA) 
or rabbit anti-rat GFAP (1:300; Millipore) primary antibodies 
overnight at 4°C. Detection was determined using donkey 
anti-mouse (1:150; streptavidin Alexa Fluor 488; Jackson 
Laboratories, Sacramento, CA, USA) or donkey antirab-
bit (1:300; Cy3; Jackson Laboratories). Sections were also 
treated with DAPI (1:200 of 1 mg/mL; Sigma-Aldrich) prior 
to mounting in FluorSave™ reagent (Calbiochem; Merck 
Millipore, Billerica, MA, USA).
F98 glioma model and survival study 
design
An F98 cellular suspension containing 100,000 luciferase-
expressing cells was implanted into the left striatum of 24 
Fischer-344 rats using the methods previously described.39 
Post operative recovery was the same as described earlier 
for animals undergoing CED procedures.
Animals were placed under brief isoflurane inhalation 
anesthetic and underwent transcranial bioluminescent imag-
ing at weekly intervals after tumor cell implantation. Each 
animal had 150 mg/kg intraperitoneal luciferin (StayBrite™; 
BioVision Inc., Milpitas, CA, USA) injected 30 minutes 
prior to imaging. Animals that had no visible transcranial 
bioluminescence 1 week after tumor implantation were 
excluded from the study.
A total of 24 animals were randomly assigned to 
three treatment groups each consisting of eight animals: 
group 1, treatment (0.6 µg/mL LBH589/P407); group 
2, vehicle-only treated control (P407/aCSF); and group 
3, untreated control. Animals in the two treatment arms 
underwent CED of either vehicle or drug 10 days after 
tumor implantation. The CED procedure was identical to 
that described earlier and used the same burr hole created 
for tumor implantation. Animals were examined daily and 
underwent bioluminescent imaging every 7 days by per-
sonnel who were blinded to the groups. Animals that had 
lost 10% of body weight or showed signs of neurological 
disability were terminated by schedule 1 killing, under-
went transcardial 4% PFA perfusion, brain explantation 
and brain preservation in 4% PFA prior to pathological 
examination. The experiment continued for 60 days when 
all surviving animals were terminated.
Postmortem histology
Rat brains were processed on a Leica Peloris and embedded 
in paraffin. Brains were sectioned at 3 µm thickness and 
stained with hematoxylin and eosin (H&E), using a Leica 
Autostainer XL as per standard histopathological technique. 
All pathological samples were examined by a neuropatholo-
gist who was blinded to the experimental groups.
Data and statistical analysis
All data analysis was performed using GraphPad Prism® 
v5 (GraphPad Software Inc., San Diego, CA, USA). IC
50
 
values were calculated from logarithmic dose–response 
curves. Multiple groups of data were compared using 
one-way analysis of variance. Significance was calculated 
using Bonferroni’s multiple comparison post hoc analysis. 
Survival curves were plotted using the Kaplan–Meier 
method, and significance was calculated using log-rank 
test. Significance was defined as *P,0.05, **P,0.01 and 
***P,0.001.
Results
synthesis and characterization of 
panobinostat-loaded nano-micelles
Colloids of panobinostat stabilized by 5% P407 in aCSF were 
successfully prepared by an emulsion-mediated process of 
organic cosolvent evaporation. The addition of a chloroform 
solution of panobinostat to P407/aCSF under stirring pro-
duced an opaque white emulsion that turned to a transparent 
clear solution after microwave heating and removal of the 
chloroform phase. DLS of a control solution of P407/aCSF 
gave an average micelle diameter of 23 nm. DLS measure-
ments of LBH589/P407-loaded nano-micelles across a 
concentration range gave an average micelle diameter of 
26 nm (Figure S1). Both unloaded and drug-loaded P407 
nano-micelles were found to have a neutral surface charge 
by zeta potential measurement.
NMR spectroscopy can detect the presence of panobinos-
tat free in solution. Drug present as either an insoluble portion 
or sequestered within the core of a polymeric micelle is not 
detectable. NMR spectroscopy of LBH589/P407 formulations 
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will indicate any dynamic equilibrium and release of the drug 
from the micelles upon further dilution in aCSF. NMR spec-
tra of LBH589/P407 colloids at neat (0.5 mg/mL), 1:3 and 
1:6 dilutions in both aCSF and P407/aCSF were taken. In a 
400 µL sample, 60 µg LBH589 was detectable, represent-
ing the presence of 30% of the drug as a molecular species 
free in solution, with 70% undetectable within the cores of 
polymeric micelles (Figure 1). Upon dilution of 0.5 mg/mL 
LBH589/P407, to a third of initial concentrations with both 
aCSF and P407/aCSF, the LBH589 NMR signal integral 
also dropped by a third. No further release of LBH589 into 
solution was observed after 24 hours. A similar observation 
was seen when fresh samples were diluted to a sixth of their 
initial concentrations with pure aCSF or P407/aCSF. For 
comparative purposes, three 200 µg LBH589 samples were 
each added to pure water, pure aCSF and a P407/aCSF solu-
tion, respectively, and agitated over 24 hours in an attempt to 
get the drug to dissolve directly. For each, up to 10 µg was 
observable as a solubilized species by NMR, indicating that 
the emulsion-mediated solvent evaporation mechanism is 
critical in achieving a high loading of drug in solution.
1H DOSY NMR was used to determine the diffu-
sion coefficients of the solvated panobinostat molecular 
 portion. A control solution of panobinostat in dimethyl 
sulfoxide yielded a diffusion coefficient of 1–2×10-10 m2/s, 
consistent with values expected for a molecule free in solu-
tion. The diffusion coefficient measured for the panobinostat 
in a LBH589/P407 colloid was found to be 0.8–2×1-10 m2/s, 
suggesting that the solvated molecular panobinostat present 
was not associated with the P407 polymer. The calculated 
diffusion coefficient for a 23-nm-diameter particle using 
the Stokes–Einstein equation was 2.8×10-11 m2/s, an order 
of magnitude lower than the NMR-observed molecular 
species. These results indicate that two separate forms of 
panobinostat were present in the nano-micellar formula-
tion having potentially different pharmacokinetic profiles 
(Figures S2 and S3).
In vitro cytotoxicity of panobinostat-
loaded P407 nano-micelles
The rat glioma cell line, F98, and human glioma cell lines, 
M059K and U87-MG, were incubated with LBH589/P407 
nano-micelles at increasing concentrations for 72 hours. 
A cell viability assay showed a dose-dependent effect. 
Nondrug-loaded P407/aCSF nano-micelles were not cyto-
toxic (Figure 2). The same assay was performed 72 hours 
???????????????????????????????
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??????????????????????
???????????
???????? ??????????? ?????????????
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? ? ?
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Figure 1 a schematic representation of the emulsion-mediated solvent evaporation preparation method.
Notes: (A) A solution of P407 (orange and blue) in aCSF is emulsified with a solution of panobinostat in chloroform. (B) The emulsion is heated to rapidly remove the 
chloroform and to sequester panobinostat (green) in the polymeric nano-micelles. A schematic representation of this process is shown in the bottom half of the figure. On the 
left is an emulsion of chcl3 containing the drug payload and stabilized by the P407 surfactant. The emulsion is heated, and the chcl3 evaporates to leave P407 nano-micelles 
containing the drug payload represented on the right. (C) after evaporation, ∼70% is loaded into the nano-micelles while 30% is present as a solvated molecular species.
Abbreviations: aCSF, artificial cerebrospinal fluid; P407, poloxamer 407.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
22
2.
13
8.
47
 o
n 
05
-A
pr
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1391
convection enhanced delivery of panobinostat
after a 6-hour exposure to LBH589/P407, to attempt to mimic 
the short tumor exposure times to the drug achieved after 
CED in vivo. Interestingly, the dose–response curves were 
similar to those observed when cells had been in contact with 
drug for longer time periods (Figures 2 and 3).
Given that the LBH589/P407 dose–response with a 
6-hour exposure time is comparable to a 72-hour exposure, 
we next investigated the cellular localization of P407 fol-
lowing increasing periods of incubation with glioma cells. 
Nondrug-loaded fluorescent rhodamine-labeled P407/aCSF 
nano-micelles were incubated with live cells (U87-MG) in 
culture prepared for microscopy to determine the intracellular 
distribution of the polymer. The fluorescent polymer was vis-
ible within the cytoplasm of the cell within 15 minutes, but 
not after 5 minutes of incubation and seemed to localize to 
the nucleus (Figure 2). This observation led us to hypothesize 
that even shorter incubation times with LBH589/P407 may 
be cytotoxic to glioma cells in vitro. LBH589/P407 had a 
dose–response effect on cell viability of the glioma stem 
cells, G26 and G144, following 30 minutes of incubation, 
which was comparable to the effect seen after 6 hours 
(Figure 2).
In vivo distribution of rhodamine-labeled 
P407-rhodamine nano-micelles in a rat 
model of acute ceD
We investigated the distribution of P407/aCSF in normal rat 
gray and white matter after acute CED. Rhodamine-labeled 
P407/aCSF was administered by CED to the corpus callosum 
and striatum of Wistar rats, which were sacrificed at 0 and 
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Figure 2 In vitro cytotoxicity of lBh589/P407 nano-micelles.
Notes: (A) Dose–response effect on cell viability following 72 hours of incubation with F98, U87-Mg and M059K glioma cell lines. Vehicle alone was not cytotoxic. 
(B) logarithmic dose–response curves of lBh589/P407 nano-micelles after 72 and 6 hours of incubation with F98, U87-Mg and M059K glioma cell lines. Dose–response 
curves of lBh589/P407 nano-micelles after 6 hours and 30 minutes of incubation with g144 and g26 patient-derived glioma stem cell lines. Tables show representative Ic50 
values for each condition. all the experiments were performed in triplicate.
Abbreviations: P407, poloxamer 407; DAPI, 4,6-Diamidino-2-phenylindole, dihydrochloride.
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48 hours post infusion. Fluorescent microscopy of sections 
from these brains was used to calculate the volume of infu-
sion in both white matter (corpus callosum) and gray matter 
(striatum). Fluorescence was detectable at both time points. 
The volume of distribution (Vd) in white and gray matter at 
both 0 and 48 hours was four to five times greater than the 
volume of infusion (Vi; Figure 4).
In vitro and in vivo toxicity of P407 nano-
micelles delivered by acute ceD
P407/aCSF nano-micelles were incubated with a pri-
mary rat hippocampal mixed glio-neuronal culture for 
72 hours and were not associated with any alteration in 
cellular density or morphology when compared to con-
trol (Figure 5). To investigate the potential neurotoxic-
ity of P407 nano-micelles after CED in vivo, we treated 
Wistar rats with intrastriatal infusion of nondrug-loaded 
P407/aCSF and analyzed their brains 72 hours and 
3 weeks after treatment in comparison to the brains of animals 
treated with aCSF alone, and untreated animals. Brains were 
histologically examined specifically for the expression of the 
neuronal marker NeuN and glial protein GFAP by immuno-
fluorescence. Juvenile animals should have relatively high 
levels of the presynaptic protein synaptophysin due to the 
increased amount of synaptogenesis in the developing brain. 
Significant synaptic toxicity and neuronal loss caused by 
infusion of P407 should therefore result in decreased levels 
of synaptophysin when compared to controls. Both toxicity 
assays did not show any difference between animals treated 
with P407/aCSF compared to aCSF-treated and untreated 
controls (Figure 5).
effect of acute ceD of panobinostat-
loaded nano-micelles on the survival of 
F98 glioma-bearing animals
Animals were randomly assigned to three groups of eight. 
Group 1 received 5 µL of LBH589/P407 at a concentra-
tion of 0.6 µg/mL administered by CED 10 days after 
tumor implantation. This dose was threefold higher than 
the IC
50
 for F98 cells in vitro after a 6-hour exposure to 
drug and was associated with an antitumor effect in vivo 
in our pilot experiments. Group 2 received P407/aCSF 
alone as a vehicle control, and group 3 received no treat-
ment. All animals that received LBH589/P407 survived the 
experimental period and were in good health. Conversely, 
untreated animals and those treated with P407 alone did 
poorly. Kaplan–Meier survival analysis showed a significant 
effect on animal survival (log-rank test, P=0.0007) after a 
single treatment with LBH589/P407 compared to untreated 
control (Figure 6).
??????????
????????????? ?????????? ?
??
??
??
?????????????? ?????????????? ?????
?????
Figure 3 Immunofluorescent microscopy of fixed U87-MG cells after exposure to fluorescent P407-rhodamine nano-micelles for 5, 15, 30 and 60 minutes. Scale bar = 25 µm.
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The brains of all animals underwent histological exami-
nation post mortem. All animals in the two control groups 
had large necrotic tumors visible on H&E-stained sections, 
including those that survived the experimental period. Con-
versely, animals that received treatment with LBH589/P407 
did not have any evidence of microscopic tumor. All experi-
mental animals had a transcranial bioluminescent signal 
1 week after implantation and before treatment, indicating 
that this result is unlikely to be due to a failure in tumor 
grafting (Figure 6).
Discussion
In this study, we showed that the pan-HDACi panobinostat 
was effective in prolonging the survival of glioma-bearing 
animals when administered in a water-soluble nano-micellar 
formulation by CED. The nano-micellar formulation was 
chosen as it provided a method by which an otherwise water-
insoluble compound could be delivered in an aqueous solution 
that did not require the use of a potentially toxic solvent, which 
is important if this therapy is to translate to the clinic. More-
over, P407 nano-micelles formulated in aCSF were not toxic 
to neurons or glia in vitro and to rat brain when administered 
by CED in vivo when compared to animals that had been 
infused with aCSF alone after a 21-day interval. The polymer 
was intracellular within 15 minutes of incubation with glioma 
cells in vitro and distributed well in both white and gray matter 
after acute CED in vivo. Fluorescent polymer remained within 
the target structure for up to 48 hours after infusion.
The F98 rat glioma model was chosen because it is univer-
sally lethal, and it displays some of the histological hallmarks 
of HGG, namely high level of mitosis and necrosis, as well as 
weak immunogenicity. It therefore serves as a good model to 
test therapies that may have an immunotherapeutic effect.40 This 
was felt to be important, due to the observation that histone 
deacetylase (HDAC) inhibition may have immunoregulatory 
effects in other malignancies, such as Hodgkin’s lymphoma 
and myeloma, and their efficacy requires an intact immune 
system.41–43 HDAC inhibition may therefore be particularly 
effective in malignancies that are poorly immunogenic and in 
tumors that are associated with an immunosuppressive microen-
vironment, such as malignant glioma.44 Even though this effect 
of HDAC inhibition has yet to be demonstrated in HGG, we did 
not want to negate any potential immunotherapeutic effect of 
panobinostat delivered by CED by using an immunocompro-
mised rat–human glioma xenograft. A rat rather than mouse 
model was used as the larger brain size is better suited to test 
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Figure 4 Distribution of P407-rhodamine nano-micelles after ceD into rat corpus callosum (white matter) and striatum (gray matter).
Notes: (A) White matter distribution 0 hour after ceD. (B) gray matter distribution 0 hour after ceD. (C) White matter distribution 48 hours after ceD. (D) gray 
matter distribution 48 hours after CED. Volume of infusion (Vi) is calculated by auto-segmentation of fluorescent signal (white image) from images from adjacent 35 µm brain 
sections using bespoke in-house software. Volume of distribution to volume of infusion ratio (Vd/Vi) indicates bulk flow of micelles via CED rather than simple injection.
Abbreviations: CED, convection enhanced delivery; P407, poloxamer 407.
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therapies administered by CED. While we recognize the limi-
tations of this model as an accurate representation of human 
HGG, it serves as a proof of concept that CED of LBH589/
P407 nano-micelles is highly efficacious in vivo.
CED of LBH589/P407 nano-micelles was associated with 
100% survival after a single infusion 10 days after tumor 
implantation, which was a dramatic and surprising result. 
The significant efficacy of LBH589/P407 nano-micelles dem-
onstrated in this study is likely to be attributable to multiple 
factors including the higher free molecular concentration 
of panobinostat achieved by the solvent-mediated emulsion 
evaporation method. In addition, the observed rapid cellular 
uptake of P407 nano-micelles in vitro may increase the 
in vivo efficacy, and there may be a sustained release of 
insoluble drug payload from the micelle core over time. We 
also show that P407 remains in the target structure for up to 
48 hours after infusion. We therefore hypothesize that the 
polymer may continue to release drug over this time as it 
biodegrades, which may also help to explain how a single 
infusion was so effective. Further investigations are required 
to prove a sustained release mechanism both in vitro and 
in vivo. In addition, the pharmacodynamics and pharma-
cokinetics of P407 after direct administration to the brain 
parenchyma are unknown and warrant further study. Bioac-
cumulation of polymer within the brain may be a concern if 
it was given repeatedly over time, and would be important 
to understand in a clinically applicable large animal model 
of intermittent CED before translation to the clinic.45,46
We also observed that CED of nondrug-loaded P407/
aCSF nano-micelles was associated with a survival advan-
tage (P=0.05; Figure 6). P407/aCSF nano-micelles were not 
cytotoxic to glioma cells in vitro. All of the animals treated 
with P407/aCSF had large necrotic tumors at the time of 
termination, even in those that survived the experimental 
period. This, in combination with the observation that 
P407/aCSF was not cytotoxic to glioma in vitro, suggests 
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Figure 5 Toxicity of P407 nano-micelles.
Notes: (A) In vitro morphology of a mixed primary rat glio-neuronal culture after 72 hours of incubation with 5% P407 in acsF relative to control. (B) synaptophysin elIsa 
of protein isolated from rat brain 21 days after infusion of either acsF or P407/acsF nano-micelles and from untreated tumor-bearing animals (one-way aNOVa Bonferroni’s 
multiple comparison test, P.0.05). (C) Immunofluorescent microscopy of fixed rat brain for neurons (NeuN) and glia (GFAP) 21 days after acute striatal infusion of either 
acsF or P407/acsF nano-micelles.
Abbreviations: aCSF, artificial cerebrospinal fluid; ANOVA, analysis of variance; DAPI, 4,6-Diamidino-2-phenylindole, dihydrochloride; ELISA, enzyme-linked immunosorbent 
assay; NS, not significant; P407, poloxamer 407.
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that this observed survival advantage is not likely to be due 
to the properties of the vehicle itself. We propose that the 
survival advantage seen in the vehicle control group may 
be due to local inflammation and mechanical damage to the 
tumor tissue caused by the infusion itself, rather than a drug 
effect. Despite this observation, the difference in survival 
between the treatment group and the vehicle control group 
was still significant (P=0.01).
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Figure 6 In vivo efficacy of LBH589/P407 after a single administration by CED in the syngeneic Fischer344/F98-Luc orthotopic rat glioma model.
Notes: animals with visible tumor bioluminescence were treated on day 10 after stereotactic implantation of 105 luciferase-expressing F98 glioma cells into the left 
striatum (large arrows on schematic). all animals had weekly scans when alive (small arrows). (A) Bioluminescent imaging revealed a loss of transcranial bioluminescence 
in treated animals compared to controls (A1) and no evidence of tumor histologically post mortem or post sacrifice (A2 H&E). (B) Kaplan–Meier survival analysis of a 60-
day experimental period showed a significant survival advantage in treated animals compared to untreated and vehicle-only controls (eight animals per group, log-rank test, 
P,0.001). all the treated animals (100%) survived.
Abbreviations: CED, convection enhanced delivery; H&E, hematoxylin and eosin; P407, poloxamer 407.
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Conclusion
HGG carries a dismal prognosis and represents an unmet 
clinical need. Current therapies are ineffective, and the 
management of the disease requires a paradigm shift if we are 
going to improve the prognosis for affected patients. Direct 
intraparenchymal infusion of drug to affected regions of 
brain by CED may provide a valid therapeutic alternative for 
patients and has met with some success in early phase clinical 
trials and in reported cases.5,7,13–15,47 Drugs with preclinical 
promise often fail to reach clinical effect as they do not cross 
the BBB when given systemically. In addition, many new 
drugs are water insoluble, which limit their use in an aqueous 
formulation, as is required for CED. We have demonstrated a 
facile method for the delivery of poorly soluble drugs by CED 
in a glioma model with translational possibility. Panobinostat 
has the potential to have a significant impact on the treatment 
of HGG when delivered in a suitable formulation for CED 
and warrants rapid translation to the clinic.
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Supplementary materials
Nuclear magnetic resonance (NMr) 
details
1H NMR experiments to investigate the behavior of the 
drug-loaded polymeric nano-micelles over time and upon 
dilution were conducted on a Varian 600 MHz VNMRS 
NMR Spectrometer fitted with a 5-mm HCN cold probe and 
using a double pulse field-gradient spin-echo water suppres-
sion pulse sequence.
As a control, 1.2 mg of as-provided bulk panobinostat 
was added to 1 mL of D
2
O, and the resultant suspension 
was moderately heated and shaken. Then, 450 µL was 
combined with 50 µL of a 2.4 mM standard solution of 
4,4-dimethyl-4-silapentane-1-sulfonic acid sodium salt 
(DSS-Na) in D
2
O in an NMR tube. The integrals of the 
DSS-Na signal between 0.72 and 0.53 ppm (two protons) 
and the panobinostat signal between 7.22 and 7.03 ppm (two 
protons) were then recorded.
A second NMR sample containing 450 µL of a 
0.4282 mg/mL (1.2 µM) solution of panobinostat in 5% 
poloxamer 407 (P407) artificial cerebrospinal fluid (aCSF) 
was combined with 50 µL of the same DSS-Na standard solu-
tion. The integrals of the DSS-Na signal between 0.66 and 
0.58 ppm (two protons) and the panobinostat signal between 
7.04 and 6.92 ppm (two protons) were then recorded.
The approximate amount of free molecular drug present 
in both samples could then be determined (precipitated solid 
fractions of the drug would not be detectable by NMR).
A third NMR sample containing 150 µL of a 0.4282 mg/mL 
(1.2 µM) solution of panobinostat in 5% P407 aCSF and 
300 µL of pre-aCSF solution was prepared (ie, a 1:3 dilution). 
Then, 50 µL of the same DSS/D
2
O standard solution used in 
the control sample was added. Repeat NMR experiments on 
this diluted sample were carried out over a 24-hour period 
with no observable change in the level of free panobinostat 
in solution.
1H diffusion-ordered NMR spectroscopy (DOSY NMR) 
was performed on a Varian 500 MHz VNMRS NMR Spec-
trometer fitted with a 5-mm AutoX DB-PFG probe to confirm 
the presence and diffusion coefficient of free panobinostat.
synthesis of rhodamine-labeled pluronic 
P407 nano-micelles
Approximately 12.66 g of P407 was dissolved in dry 
acetonitrile (15 mL) and added dropwise to an excess 
amount, 1.62 g of N,N-carbonyldiimidazole (CDI) in dry 
acetonitrile (15 mL) at room temperature during a 2-hour 
period under nitrogen atmosphere. The resulting mixture 
was kept stirring for a further 2 hours before the removal 
of unreacted CDI by the addition of 0.2 mL of water. The 
neutralized solution was stirred for a further 20 minutes, 
then added dropwise over a 2-hour period to 10 mL of 1, 
2-ethylenediamine at room temperature. The solution was 
allowed to react for 12 hours before the removal of excess 
1,2-ethylenediamine by rotary evaporation to form a viscous 
transparent oil. This solution was transferred to a section 
of dialysis tubing MW, 3500 cutoff) and dialyzed against 
water for 5 days. The dialyzed solution was freeze-dried to 
isolate the P407-NH
2
 intermediate for use in the rhodamine 
cross-linking reaction.
Approximately 10 mL of dimethylformamide contain-
ing 0.323 g of P407-NH
2
 was degassed under nitrogen for 
10 minutes before 67.5 mg of rhodamine isothiocyanate was 
dissolved into it. The reaction vial was wrapped in foil to 
prevent photobleaching of the rhodamine moiety and main-
tained under nitrogen for 12 hours to allow the rhodamine 
to couple to the pendant amine. The product solution was 
decanted into dialysis tubing (MW, 3500 cutoff) and dia-
lyzed against a weak NaOH solution maintained at pH 8.0 
for 7 days before the rhodamine-labeled P407 product was 
isolated by freeze-drying to form a bright purple product 
which was crystalline in appearance.
?
?
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Figure S1 Dls number plot for P407 micelle solutions containing 0–1.44 mM 
concentration of panobinostat (lBh589).
Abbreviations: DLS, dynamic light scattering; P407, poloxamer 407.
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Figure S2 Plot of a DOsY NMr spectrum showing the characteristic chemical shifts for panobinostat (lBh589) after water signal suppression in a 5% P407 solution 
synthesized using the emulsion evaporation method.
Abbreviations: DOSY NMR, diffusion-ordered nuclear magnetic resonance spectroscopy; P407, poloxamer 407.
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Figure S3 A plot of diffusion coefficients for the various species of panobinostat (LBH589) present in solution.
Notes: The blue plot is the data taken from Dls of an lBh589/P407 micelle. The black lines represent the expected domain for small molecule species free in solution. 
The red lines indicate the range of diffusion coefficients observed for molecular LBH589 as calculated from NMR data.
Abbreviations: aCSF, artificial cerebrospinal fluid; DLS, dynamic light scattering; NMR, nuclear magnetic resonance; P407, poloxamer 407.
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